Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2  by unknown
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Reductions in mortality that are realistically moderate (for 
example, “only” 20 to 25%) are important, especially if 
produced by widely practicable treatments for common 
cduses of death, but reliable assessment of them may require 
strict randomization of several thousand patients. The Second 
International Study of Infarct Survival (ISIS-2) has randomly 
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and 38% f 1.5 for the combination of streptokiiase and 
aspirin). 
Streptokinase was associated with an excess of bteeds 
requiring transfusien (0.5% versus 0.2%) and of continned 
cerebral hemorrhage (0.1% versus O.O%), but witb fewer 
other strokes (0.6% versus 0.8%). These “other” strokes 
may have inelu6ed a few undiagnosed cerebral hemor- 
rhages, but still tbere was no increase in total strokes (0.7% 
streptokinase versus 0.8% ptaeeho infusion). Asphin signii- 
icantly reduced nonfatal reidaretion (1.0% versus 2.0%) 
and nonfatal stroke (0.3% versus 0.6%), and was net 
associated with any sign&ant increase in cerebral hemor- 
rhage or  in bleeds requiring tramfusion. An excess of 
nonfatal reinfaretien was reported wken streptakhtase was 
used atone, but this appeared to he entirety a&led by the 
additkm of aspirtn. 
Those allocated the combination of streptokinase and 
aspirin had signiticantly fewer reinfarclions (1.8% versus 
2.9%), strokes (0.6% versus l.l%), and deaths (8.0% 
versus 13.2%) than those allocated neither. The diierences 
in vaseular and in all cause mortality produced by strepto- 
kinase and by aspirin remain biibty significant (2p C 0.001 
for each) after the medii of I5 months of follow-up thus 
far available. 
(J Am Co11 Cardiol1988:12:3A43A) 
assessed, with placebo control, the separate and combined 
effects of intravenous streptokinase (a single infusion of I.5 
million units over about I h) and of oral aspirin (164 mglday 
for I month) in 17,187 patients with suspected acute myocar- 
dial infarction. This report is hased on the full results pub- 
lished io :hc Lancet (1). where the COkIbOrdtOrS and partlci- 
pating centers are listed. 
Streptokinase. During the 1960s and 1970s. several small 
trials of librinolytic therapy yielded apparently conflicting 
results, but an overview (2) of their findings indicated that 
fibrinolytic therapy could reduce mortality by about one- 
quarter. This overview also indicated that mortality was 
4A IS IS-2  COLLABORATIVE G R O U P  
I N T R A V E N O U S  STREPTOKINASE A N D  ORAL A S P I R I N  I N  ACUTE MYOCARDIAL  INFARCTION 
JACC Vol. 12, N O .  6 
December 1988:3A-13A 
reduced not only among patients treated early (for example. 
O-6 h after the onset of pain), but also among those treated 
later (for example, between 6-12 h, or even after a delay of 
more than I2 h). In ISIS-2, therefore, patients were eligible 
up to 24 h from the onset of pain, though the aim was always 
to treat them as promptly as possible. 
Aspirin. An overview of the 10 randomized trials of 
long-term aspirin or other antiplatelet agents among patients 
with a history of previous myocardisl infarction found a 25% 
reduction in “serious vascular events” (reinfarction, stroke 
or vascular death). and two trials in unstable angina pro- 
duced similar results (3). 
Methods 
Patients. To encourage recruitment, the trial procedures 
were as simple as possible (4): randomization involved only 
a telephone call and no forms, the use of ancillary treatments 
was not restricted, and follow-up after discharge involved 
only mortality, through government records wherever pos- 
sible. As a result, 417 hospitals in I6 countries randomized a 
total of 17,187 patients. 
Treatment. A “2 x 2 factorial” study design was used 
(5). Half of all patients were allocated randomly to receive 
streptokinase (I .5 million units of “Streptase”) and half to 
receive matching placebo (hepatitis-B-antigen-free albumin), 
infused intravenously over about I h in 5G2-250 ml of normal 
saline solution, starting immediately. Half of all patients 
were also allocated randomly to receive oral aspirin (exact 
dose: 162.5 mg in enteric-coated tablets) and half to receive 
matching placebo (enter&coated starch tablets), given daily 
for I month from a calendar pack, starting immediately with 
the first tablet crushed, sucked or chewed for a rapid 
antiplatelet effect. Hence, there were four treatment groups: 
streptokinase alone, aspirin alone, both, or  neither. 
The trial treatments were to be interrupted only if this 
was thought to be clearly indicated by the responsible 
physician. In all other respects, physicians were free to use 
whatever additional therapy they considered necessary. For 
example, although physicians were asked to state just before 
randomizing each patient, whether or not they “planned” to 
add anticoagulants to the trial treatments for that particular 
patient, their plan could be altered if some contraindication 
developed. 
Eligibility. Patients were eligible if they were thought to 
be u+r!ti)t M /I of the onset of symptoms of suspecfed 
myocardial infimrion. and to have no clear indication for, or 
contraindication to, streptokinase or aspirin. (Absolute con- 
traindications at the start of ISIS-2 were any history of 
stroke, or of gastrointestinal hemorrhage or ulcer, although 
in retrospect this may have been too restrictive. Possible 
contraindications included recent arterial puncture, recent 
severe trauma, severe persistent hypertension, allergy to 
streptokinase or aspirin, low risk of cardiac death, or some 
othe. life-threatening disease.) The Fundamental criterion for 
entry was that the responsible physician was uncertain 
whether, for a particular patient, treatment with streptoki- 
nase or aspirin was indicated. Electrocardiographic changes 
at entry were not a requirement. 
Randomization. Entry to the study was by a 24 h tele- 
phone service based in Berlin for G,rmany, Gent and 
Brussells for Belgium, Valencia for Spain, Bellinzona for 
Aus!ria and Switzerland, Lyon for France and Oxford for all 
other countries. Before randomization some detaiis were 
recorded (directly on a computer in Oxford and Lyon, or 
first on computer-generated randomization lists elsewhere), 
including patient identifiers, age, systolic blood pressure, 
hours frdm onset of the episode of pain that led to admission, 
aspirin use Turing the week before entry, and “planned” 
treatment in hospital (that is, whether non-trial treatment 
was likely to include any aspirin, anticoagulants or intrave- 
nous beta-adrenergic blockers). If any prerandomization 
details were incomplete then randomization was not to be 
issued, and such patients were not part of the trial. In Oxford 
and Lyon, the computer allocated treatment using a “mini- 
mization’. algorithm (6) to help avoid any chance differences 
in prognostic features recorded at entry. On January 24, 
1986, a programming error led to more of the patients 
randomized at Oxford during a period of about 2 months 
being allocated to placebo infusion and placebo tablets. 
Correction of this programming error restored exact balance 
by August 1986. (The apparent effects of streptokinase and 
of aspirin among patients randomized in Oxford between 
January 24 and August 31, 1986, were, however, the same as 
in all other patients [I].) After allocation of a specific 
treatment pack containing active or placebo trial treatments, 
the patient was irrevocably in the trial. Whether or not the 
treatment in the pack was actually given, patients remained 
in their originally allocated treatment group for an “inten- 
tion-to-treat” analysis, and the few second entries were 
disregarded. 
Dischrge. At discharge, a prerandomization electrocar- 
diogram (ECG) and a simple single-sided form were returned 
to the trial office. This “discharge form” provided further 
identifiers to assist central mortality follow-up after dis- 
charge, as well as brief details of compliance with study 
treatments in hospital, other drug use in hospital and at 
discharge, any apparent side-effects of treatment, and major 
events in hospital (bleeding. cardiac rupture, reinfarction, 
cardiac arrest, stroke, and death). Each ECG was read 
“blind” of treatment by three observers (with adjudication 
by the trial coordinator if no two agreed). If bundle branch 
block was present (6% of ECGs) this alone was noted, 
otherwise the ECG categories (as in ISIS-I 171) were: 
Inferior STelevafion (29%): ~3 mm in the sum of leads II 
t 111 + aVF; 
Anterior ST elevorion (25%): (a) k6 mm in the sum of 
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‘Transienl ischemic attacks (TIA) lasting24 h or less were not recorded routmely. and the 51x \Irokec rcclawiied on revtcw as lnns~nt lschcmlc altacks arc 
excluded (2 strcntokinase only. 2 aspann only. I  bolh. I  nather). In addntum to the 7 hemorrhage> “confirmed” (by CT scan or autopsy). 3 ‘*posableT (2 
slreptokinase only. I  streplokinase &aspirin) were reported. All IO  occurred on days C-l. 9 died m hospital and the one turvivw Wreprokmase &  aspmn. wth 
CT confirmation) was severely disabled. 
leads V, + V, + V, and/or(b) 26 mm in leads V, + V, + V, 
and/or(c) 22 mm in leads I + aVL; 
Inferior and anterior ST elevation (2%): both of the 
above: 
ST depression (8%): none of the above, but with ST 
depression as extreme as the ST elevations required above. 
Other abnormality (27%): none of the above, but with (a) 
pathologic Q waves (16%) 22 mm in any lead other than 
aVR or VI, or(b) no Q waves but T wave invers;o,r (I I%) in 
any lead other than aVR or V,, or(c) any conduction defect 
(for example, atrioventricmar block) or any arrhythmia (for 
example, atrial fibrillation, supraventricular tachycardia): 
“Normal” (2%): any remaining electrocardiograms. 
Follow-up. The present report is of outcome by allocated 
treatment among all randomized patients, except those 206 
patients (102 active streptokinase versus I04 placebo infu- 
sion; 95 active aspirin versus 1 I I placebo tablets) for whom 
discharge forms had not yet been obtained by July 1988. 
Discharge was at a median of IO days, and mortality fol- 
low-up was for a maximum of 34 months and a median of I5 
months. The completeness of follow-up is 99% to discharge, 
97% to week 5 and %% to January 1, 1988. (About nine- 
ten!hs of all deaths in the first 5 weelis occur in hospital, so 
it is probable that more than 98% of the 5-week deaths 
among the !7.187 randomized patients are included in the 
present analysis.) 
All deaths were reviewed b!md of treatment allocation by 
the trial coordinator. Causes of death were subdivided into 
“nonvascular” (that is. definitely nonvascular) and “vas- 
cular” (that is, definitely or possibly vascular). The latter, as 
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specified in the original protocol, includes all deaths attrib- 
uted to cardiac, certbral, hemorrhagic, other vascula!, or 
unknown causes !that is, 9th International Classification of 
Disease categories 390-459, 530-535, or 797-799). Those 
deaths finally classified as nonvascular were not adversely 
associated with treatment (Table I), so their addition to the 
analyses of vascular mortality to yield analyses of all-catase 
mortality would not weaken the apparent effects of treat- 
ment. For all reports of stroke on the discharge form, further 
clinical details (including any relevant investigations, such as 
computerised tomographic (CT) scans and autopsy reports) 
were :iy~s!cd. Confirmation or refutatiori of the s!roke and 
its etioligy was based on blind review of these records by a 
neurologist. All strokes not confirmed by CT scan or autopsy 
as cerebral hemorrhages are described as being of “ischemic 
or unknown” etiology. For while most were probably ische- 
mic, a few may have been due to undiagnosed hemorrhage. 
For each stroke, the “likely residual disability” was classi- 
fied on the discharge form as nonsignihcant (modified Rankin 
[8] grade O-l), moderate (grade 2-3) or severe (grade 4-5): in 
the present report, the latter two categories are merged. The 
few reports of possible anaphylactic shock were also re- 
viewed blind of treatment allocation. 
Statistical methods. The protocol specified three main 
analyses. These involved assessment of the effects of intra- 
venous streptokinase on vascular mortality during (a) the 
first 5 weeks, and (b) the entire period up to January 1, 1988 
(that is, a median follow-up of I5 months), and of the effects 
of 1 month of oral aspirin on vascular mortality during the 
first 5 weeks (that is, days O-35, the period of antiplatelet 
cover). It also specified one “most important subsidiary 
analysis”, involving separate assessment of the effects of 
streptokinase on 5-week vascular mortality among patients 
randomized O-4,5-12 and 13-24 h after the onset of symp 
ioms, and six other subsidiary analyses (see Results). 
Comparisons of survival to January I, 1988 involve time 
to death analyses using log-rank methods (9) (with exact 
variance calculations), but for events in hospital and deaths 
during the first 5 weeks comparisons involve simple analyses 
(3) of total numbers affected. Most results are presented in 
terms of changes in the odds of death: for example, a change 
from 10% dead (odds 10/90) to 8% dead (odds 8/Y2) involves 
the odds ratio of (8/92) i (IO&O). or 0.78, and is therefore 
described as a 22% reduction in the odds of death (3). rather 
than as a 20% reduction in the risk of death. Odds ratios and 
reductions in odds are generally given with either 95% 
confidence intervals of ? I standard deviation. Two-sided p 
values (2~) are cited, even in subgroup analyses where 
one-sided p values (Ip) might be more appropriate (9). 
During recruitment, interim results on events in hospital 
were reviewed about twice a year by an independent data 
monitoring committee. In the light of these interim analyses, 
and of any other evidence or advice they wished to seek, the 
data monitoring committee were to advise the chairman of 
the steering committee if, in their view, there was at any time 
proof beyond reasonable doubt that for all. or for some, 
types of patients either treatment was clearly indicated or 
clearly contraindicated. Otherwise, the steering committee, 
collaborators, and administrative staff (except those who 
produced the confidential analyses) would remain ignorant 
of the interim results. In January 1987, the data monitoring 
commitiee reported (IO) that among patients entered O-4 h 
after pain onset, there was clear evidence that mortality in 
hospital had been reduced by streptokinase. Randomization 
continued for those patients where, in the view of the 
physician actually responsible for the patient, substantial 
uncertainty remained about the appropriateness of treat- 
ment: this was stiii often the case not only for patien!s more 
than 4 h after pain onset (for whom interim results were not 
made available during the trial), but also for some presenting 
earlier. 
Results 
Study results. 17,187 patients were randomized between 
March 5, 1985 and December 31, 1987. This large size (and 
:he use of minimization) ensured good balance between the 
treatment groups for the main prerandomization prognostic 
features that were measured, and should do likewise for 
those that were not. Among those discharged alive, the 
infusion was completed in 98% of patients allocated placebo 
and in 92% allocated streptokinase. Since the librinolytic 
effect of an infusion that has been interrupted (usually 
because of some side effect) may be substantial, effective 
compliance with streptokinase allocation is likely to be wel! 
over 92%. For aspirin, 94% of those discharged alive in both 
active and placebo groups continued their trial tablets 
throughout the hospital stay, when nine-tenths of 5 week 
mortality occurred (thus, among those dying before week 5, 
compliance must have been YO-95%). 
Comparison of the 8,592 Patients Allocated 
Intravenous Streptokinase With the 8,595 
Allocated Placebo I&ion 
E&et on vascular mortality in first 5 weeks (Fig. 1A and 3) 
and later (Fig. 2A). During the first 5 weeks there were 791 
(9.7%) vascular deaths in the streptokinase-allocated group 
compared with I.029 (12.0%) in the placebo group. This 25% 
+ 4 reduction in the odds of death in the streptokinase group 
is highly significant (2p < O.OWOl), with 95% confidence 
interval ranging from 18% to 32%. Several years of further 
follow-up will be needed to see how long these early gains 
persist. Thus far, with median follow-up I5 months, there 
has been a slight and nonsignificant further divergence after 
day 35 (Fig. 2A). Hence, the overall difference, including 
both early and late vascular mortality, remains highly signif- 
icant (2p < 0.00001). Nonvascular deaths were evenly ds- 
tributed (32 versus 32: Table I), so all-cause mortality was 
also highly significantly reduced (2p < O.OOl), both in the 
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first 5 weeks and in the entire study period to January I. 
1988. 
Influence of delay from pain onset to randomization on size 
of effect of streptokinase on S-week vascular mortality (Fig. 
3A). Among patients randomired O-4. 5-12 and IS24 h 
after the onset of pain, the reductions in the odds of vascular 
death were 35% ? 6(2p < 0.00001). 16% +_ 7 (2~ = 0.02) and 
21% + 12 (2p = 0.08). The reduction is greatest in Iho,e 
randomized within 4 h. but it is still significant (17% 2 6. ?p 
= 0.004) in those randomized within 5-24 h. (If p  value\ are 
to be used at all to help decide whether. m a clearly positive 
trial, particular subgroups are also positive then one-tailed p 
values may be preferred: these are. however. simply half the 
cited “2~” values, for example, Ip = 0.002 instead of 2p = 
0 004.) Within the early period, there was no evidence that 
benefit was substantially greater among patients randomized 
within I h  than among those randomized after 2-4 h. 
Detailed subdivision of the effects of delay are provided in 
Fig. 3, but the confidence intervals are too wide for the 
pattern to be clear without also using the evidence from 
other trials (see Discussion). 
Fiqure I. Cumulative vaseul~r mortality in dajs O-35. A, All pa-  
uwh allocated active weptokmse verws all allocated a placeho 
mfuvon: B. All patient\ allocated active dspsnn verw all allocated 
placeu~ table!\: and C, All pahen& allocated both aclive trearmem\ 
verw\ Jl allocated neither. (Stati4cal le\t\ 13)  10 day 3i-obterved 
number or  v;rcuiar dearh* in acoie irealmeni group mmu\ expected 
number. and th: standard deviarion of !hn ddTerence: (At -I is.3 2 
20.2. (B) -  IO5 3 ? 20.2: and (0 -  II?.1 ? 14.3.1 From Lcrnc VI (I). 
wth oermwon. 
Effect of streptokinase on other clinical events in hospital 
(Tables I and 2). Hypotension and bradycardia were re-  
ported far more commonly iq the streptokinase group than in 
ns control (10.0% vcrsu? 2.0%). generally during the 60 min 
infusion or  very shortly after. The excess was not related lo 
the initial blood pressure-indeed. even among the 431 with 
Figure 2. Life-table estimat- of 12 monlh and 24 month survival. 
Median follow-up I5 d,onrh$, maximum 34 months. (Log rank ~CF~C 
(9)  10 January I. 1988: (A) -133.5 2 26.7 (6)  -88.5 2 26.7 (C) 
-I IO 7 ? 19.0.) From Lomw (I). wnh permitrion. 
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Figure 3. Reductions in odds of vascular death in days 
O-35, subdivided by time from pain onset. The size of the 
squares in Figures 3 and 5 indicate how much informa- 
tion is available (3). and 95% conldence intervals are 
denoted by lines or  diamonds. (SD = standard devia- 
tion.) From Lancer (I), with permission. 
0.5 *.0 
a systolic blood pressure < 100 mm Hg it was no greater than 
average. Reports of allergic reactions (4.4% versus 0.9%) 
were in most cases confined to shivering, pyrexia, or rashes, 
also generally during or just after the streptokinase infusion; 
on blind review, however, no reports of anaphylactic shock 
were confirmed. 22% of patients received prophylactic ste- 
roids, but this strategy did not appear to alter the reported 
rate of allergic reactions (3.3% + 0.5 excess with streptoki- 
nase among patients given prophylactic steroids and 3.6% f 
0.3 among those not given prophylactic steroids). Bruising or 
“minor” bleeding (for example, oozing from puncture sites, 
microscopic hematuria, blood-streaked vomit or sputum) 
was reported more commonly among streptokinase-allo- 
cated patients (3.5% versus I .O%), and there was also a small 
excess (0.3% 2 0. I) of bleeds requiring transfusion (“major” 
bleeds: 0.5% versus 0.2%, 2p < 0.001). This excess appeared 
similar whether or noi sirepiokinase was used with aspirin, 
and even the excess of minor bleeding caused by streptoki- 
nase appeared to be only slightly greater in the presence of 
1:s 
aspirin (2.8% + 0.3) ,than in its absence (2.3% & 0.3). The 
excess of any bleeds caused by streptokinase did, however, 
depend on whether intravenous, subcutaneous, or no hepa- 
tin use was planned (absolute excesses 5.3%, 2.6%, or l.S%, 
respectively: Table 2), as did the excess of major bleeds 
(0.7%. 0.4%. or 0.0%: but, the lack of any excess of major 
bleeds in the absence of heparin involved only 8 of 2,903 
streptokinase versus 8 of 2,907 control patients). There was 
no unusual excess of bleeds or of hypotension among the 401 
patients who were a8ed 80 or over, or among the 178 with a 
systolic blood pressure of 200 mm Hg or more. 
There was a significant excess (0.1% -t 0.03) of confirmed 
cerebral hemorrhage with streptokinase (7 versus 0; 2p c 
0.02), all occurring on the day of randomization or the 
following day and all followed by death (six patients) or 
severe disability (one patient). During this early period there 
was also a slight but nonsignificant excess of “other” 
strokes (20 versus, 13), some of which may also have 
involved cerebral hemorrhage. But, although streptokinase 
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Table 2. Reported Side Effects Associated With Streptokinaso and 
Placebo Infusions 
At\ol”tc 
Treatmen! ,dl~c~fwn <‘rces, wth 
\treptokm.ire 
ACllVC PldCdXl I I  SK-% 
Side ebct streptokmw lnfurlon plahol 
No. randomized 11.592 x.595 
No. with discharge form x.490 X.491 
“Signiticam” 847(100% !-3 1’ It%1 79% 
hypotenwn and/or 
bradycardia 
Allergic reacl,on 374 (4 4%) 73 IO  95;) 15% 
Any bleed 343 (4 lx) 99Cl ?%I 29%. 
GilSlRllIlt~Stld lcoll2%l zncoz%) 0 9% 
SylllptWllS 
Arrhythmias 107 11.3%) 28 V I  3%) 0 9% 
Miscellaneous 99 (1.2%) I6 10 ?7d I ng 
Patients with any of the 1.534118.I%) 383 (4 5?) 13 6% 
above 
*The bleeding caused by streptokmase depended on whether the planned 
treatment Involved mtravenous heparm. subwanenw hew#w wiy. VT ho 
heparin (absolute excesses 5.3% S D  r  0.65. 2 6% S D  + 0 34. or I  5% S D  2 
0.36 respectively: 2p < O.Mx)I for trend). 
Comparison of the 8,587 Patients Allocated 
Oral Aspirin With the 8,600 Allocated Placebo 
Tablets 
Effect on vascular mortality in the first 5 weeks (Fig. IB 
and 3) and later (Fig. 25). During the first 5 weeks there 
were 804 (9.4%) vascular deaths in the aspirin-allocated 
group compared with I .016 (I 1.8%) in the placebo control 
group Tht\ 23% ? 4 reduction in the odds of death m the 
arp~nn group 15 highly significant (2p < 0 00001). with 95% 
,x.ft.!~.~ mterval rangin; f:sm 15% to 30%. As was the 
case for \treptokinase. several years of further follow-up will 
be needed to \ee how long these early gains persist. Thus far. 
durmg a median follow-up of 15 months. there has been a 
\hght and non~rgniticant convergence after day 35 (Fig. 2B). 
but the overall difference. including both early and late 
vascalnr mortality, remains highly significant (2p < 0.001). 
There were fewer nonvascular deaths among aspirm- 
allocated pattents (25 versus 39: NS: Table I). so all cause 
mortahty was also highly significantly reduced (2p < 0.001). 
both m :he Errt 5 weeks and in the entire study penod to 
January I, 1988. 
Effect of aspirin on other clinical events in hospital (Table 
I). Bleeds requiring transfusion (“major” bleeds) were re-  
ported with a simdar frequency in both groups (0.4% Jspirin 
versus 0 4% placebo). Apart from a small absolute excess 
(0.6% -C 0.2: Zp < 0.01) of “minor” bleeds. there were no 
stgndicant adverse effects of the low dose aspirin regimen 
tested. In particular, there was no signlticant excess of 
cerebral hemorrhage. There were significant reductions in 
reinfarction (2~ < O.OGtJOI), in cardiac arrest (2p : 0.01). and 
in stroke (2~ < 0.01). but there is a considerable overlap 
be!ween early deaths and these eve& reported in hospital 
smce some patients suffered both. To avoid double-counting 
m the assessment of any effects of aspirin over and above 
those on mortality, attention may be restricted to patients 
discharged alive. When this was done, aspirin was still 
associated with significant reducttons in reinfarctior. ‘I .c)o/o 
versus 2.0%) and in stroke (0.3% versus 0.6%). 
Comparison of the 4,292 Patients A/located the 
Combination of Streptokinase and Aspirin With 
the 4,300 Patierzts Allocated Neither 
Effect on vase&r mortality in the first 5 weeks (Fig. tC, 3, 
and 4) and later (Fig. ZC). Mortality among patient. allo- 
cated the combination of both agents was significantly less 
than that among patients allocated both placebos (42% I 5 
reduction by the combination. with 95% confidence limits 
347+50%: 2p < O.OOO@l). Indeed, the combination was 
significantly (2p < O.OOBl: better than either active treatment 
on its own. After the first 5 weeks there was no indication of 
any further convergence or  divergence (Fig. 2C). Hence. the 
overal: difference in vascular mortality, including both early 
and late deaths, remains highly significant (2 p i O.ooOlJ. 
Nonvascular deaths were slightly fewer among treated than 
among control patients, so all cause mortality was atso 
highly significantly reduced (2 p i O.OOOl) in the first 5 weeks 
and in the entire study period to January I, 1988. 
I he beneticiai etiects of streptokinase and of aspirin on 
mortality appear to be largely independent of each other 
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Figure 4. Cumulative wscuiar mortality rate in days O-35. Patients 
allocakd (i) active streplokinase only, (ii) active aspirin only, (iii) 
bolh active treatments. and (iv) neither treatment. From Lancer (I). 
with permission. 
(Fig. 4). Streptokinase significantly reduced 5 week vascular 
mortality both among patients allocated to aspirin and 
among those allocated placebo tablets (reductions in the 
odds of death by streptokinase: 28% t 6 and 23% t 6, 
respectively: each 2p < 0.0001). Similarly, aspirin reduced 
mortality irrespective of whether patients were allocated 
streptokinase or placebo infusions (reductions in the odds of 
_______.’ __I... 
Aspirin produced similar-sized reductions in mortality 
among patients treated early and those treated late after the 
onset of symptoms (odds reduction at O-4,5-12 and 13-24 h: 
25% + 7, 21% + 7, and 21% 2 12, respectively), while the 
effects of streptokinase appeared greatest among those 
treated earliest. So when patients allocated the combination 
of both streptokinase and aspirin are compared with those 
allocated neither active drug, the odds of death were signif- 
icantly reduced among patients randomized t&4 h (53% ? 8 
reduction: 2p < 0.00001). 5-12 h (32% ? 9 reduction; 2p < 
0.0001) and 13-24 h (38% + I5 reduction; 2p = 0.01) after 
pain onset. 
Effects of the combination of both agents on other cliiical 
events in hospital (Table 1). As for streptokinase alone, the 
combination of streptokinase and aspirin was associated 
with a 0.3% Z? 0. I excess of “major” bleeds when compared 
with patients receiving neither active treatment. A 0.1% 
excess of cerebral hemorrhage was still observed, but this 
was offs :t by shortfalls of 0.3% in other strokes with death in 
hospital of 0.1% in disabling strokes and of 0.2% in other 
strokes with discharge alive. Overall, therefore, the combi- 
nation of streptokinase and aspirin was associated with 0.5% 
-C 0.2 fewer strokes (0.6% versus 1.1%: 2p = 0.02). It was 
also associated with fewer reinfarctions, cardiac ruptures 
and cardiac arrests in hospital, but most of these differences 
were among patients who died in hospital and so have 
already been accounted for in the mortality analyses. 
Discussion 
The size of this trial ensures that the reductions in 
vascular mortality (or in all-cause mortality) that have been 
demonstrated for intravenous streptokinase and for oral 
aspirin are both definite. The benefits appeared to be largely 
independent of each other-that is, streptokinase reduced 
mortality by a roughly similar additional amount irrespective 
of whether aspirin was used or not, and vice versa. Conse- 
quently, the combination of both active drugs produced a 
reduction in the odds of death at 5 weeks that was far larger 
(42% + 5 for both agents versus neither) than that produced 
by either drug alone, with such a narrow 95% confidence 
interval for this reduction (34% to 50%) that the possibility of 
there being little real benefit is absolutely excluded. This 
does not, ofcourse, guarantee that the risk reductions will be 
exactly the same size in each specific category of future 
patients, but it does provide strong indirect evidence that 
these treatments will generally reduce coronary mortality 
substantially (see Lancer report [I] for expanded discussion 
of this). Generalizing too far may lead to patients being 
treated inappropriately for if streptokinase is used where it 
can confer no benefit then it may cause I or 2 unnecessary 
deaths per 1,000 patients. But, so too may failing to gener- 
alize far enough for if aspirin and streptokinase are not used 
.*bcre :bri coiiid confer bcncl: :bcn this may !cad :o abou; 
50 avoidable deaths per 1,000 patients. 
Fibrinolytic therapy. The principal findings were that 
s:reptokinase improves 5 week survival, that this benefit 
persists for some years, and that (although the effects appear 
greatest among patients treated most promptly) fibrinolytic 
therapy appears to produce some benefit even among those 
treated up to 24 h from pain onset. 
The hypothesis that fibrinolytic therapy might be beneli- 
cial more than 6 h after the pain onset was generated by an 
overview (2) of previous trials (Fig. 5). Among such patients 
in ISIS-2 streptokinase produced a reduction in vascular 
mortality that was significant at week 5 (2p = 0.02) and that 
has persisted well after week 5, with a median of I5 months 
of follow-up thus far (2p = 0.004 for lot. rank (9) test of effect 
of streptokinase on oveiall mortality among 6,477 patients 
entered 7-24 h after the onset of pain). To obtain the most 
reliable test of this hypothesis, the results of ISIS-2 need to 
be considered along with those from other recent uncon- 
founded randomized trials of rapid high dose (I.5 million 
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Figure 5. Reductions in the odds of early 
dealh, subdivided by time from pain onset: 
over&v of the six randomized trials of 1.5 
millton unit5 intravenous streptokinase (and of 
late treatment in other trials (21). The infasron 
&ration was 60 min in five trials (I, I I-13, 15)  
aqd 30 min in the trial reported by White et al. 
(16). Square sizes and 95% confidence rnrer-  
vals (CD are as in Figure 3. The difference 
between the 31% reduction O-3 h after parn 
onset and the 14% reduction 6-24 h after pain 
onset is 17% * 7: 2p < 0.02. (SD = standard 
deviation.) From Lancer (I). with permissron. 
units within I h)  intravenous streptokinase regimens. Only 
two such trials (I 1.12) have included patients presenting 
more than 6 h from pain onset, and these, along with ISIS-2 
(I) and ISAM (13). are the four largest trials of a rapid high 
dose regimen. There were no significant differences between 
their findings, and an overview of these results (Fig. 5)  
provides significant confirmation of benefit among patients 
treated after 6 h. For patients treated within O-3 h and 3-6 h 
of the onset of pain, the data now available from ISIS-Z, 
GISSI, and the other trials should leave little doubt that 
tibrinolytic therapy reduces mortality-indeed, even the 
lower 95% confidence limits for the estimated mortality 
reductions are well away From zero. In contrast, although 
the observed mortality reduction is statistica!ly significant 
(2p = 0.02) among patients treated more than 6 h after pain 
onset, it is still consistent with there being only a small 
benefit. In view of the pattern of a gradual diminution oi 
benefit with delay, however, and in view of the benefit from 
streptokinase after 6 h in the previous trials (Fig. 5). it is 
likely that tibrinolytic therapy does produce some worth- 
while benefit even when used 7-24 h after the onset of pain. 
But, no analyses of ISIS-2 alone are likely to establish 
reliably which such patients can expect the greatest propor-  
tional benefit. (For example, the reduction in 5 week vascu- 
lar mortality by streptokinase in patients treated 7 to 24 h 
after the onset of pain was 22% ? 10 ]2p < O.OS] among those 
with ST elevation recorded on their prerandomization ECG. 
which is similar to the 18% -C 7 ]2p = 0.021 mortality 
reduction among all patients entered late.) 
When deciding whether to use librinolytic therapy in 
patrents with suspected acute myocardial infarction. partic- 
ularly those presenting late after the onset of pain, it 
is necessarv to consider not only the possible benefits 
but also the possible risks. / I least for streptokinase. 
however, the risks are small: side effects such as hypo- 
tension, allergic reactions, or  minor bleeding may be worry- 
ing but do not usually cause patients managed in hospital 
any serious problem, and the recent trials (ISIS-2, ISIS-2 
pilot. GISSI and ISAM) have demonstrated that serious 
side effects of the rapid high dose intravenous strepto- 
kinasc regimen are rare-only about three bleeds requiring 
transfusron and about I or  2 cerebral hemorrhages per  
l,OtM patients, with no significant increase in the rorol 
number of strokes (ISIS-2: 61 streptokinase versus 67 
placebo; GISSI: 49 versus 40; ISAM: 5 versus 0: ISIS-2 
pilot: 2  of 413 versus 5 of 206 [equrvalent to I/206 versus 
S/206]; other trials: I versus 0: total: 117 versus 112). On 
the other hand, the risk of coronary death in patients 
with suspected acute myocardial infarction may be high, 
even among those without pronounced ST elevation on 
their ECG or  among those admitted late after symptom 
onset. A reduction in mortality of “only” l4%, as sug- 
gested by the trial results for those presenting after 6 h. 
would typically avoid about 15-20 early deaths among 
every l,OOtl patients, which compares favorably with the 
small number of serious complications that might be ex- 
pected. 
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Table 3. Percent Reduction in Vascular Events Observed in Trials 
of Medium- and Long-Term Antiplatelet Therapy for Suspected or
Detinite Myocardial Infarction 
Percent Reduction Observed WI I I I  
Ani~platelel Therapy (‘Z z S D )  
Loop-Term 
Acute MI I I S I S -  Following MI 
Vascular Event Inal” + pdot’; II0 trids !SJ !  
Nonfatal stroke* 46% + 17 429 + I I  
Nonfatal reinfarctlon’ 49%+9 31% F 5 
Varcular death 23% + 4 IS% 2 5 
Any vascular even, 28% 2 4 25% f  5 
l Woh surwal 10 week 5 I ”  IS IS-2  and to Ihe et-d of the scheduled 
treahnent period m the IO  long-term trials *in the IS IS .2  pdol lnal (I?) there 
were 27/313 l&h’%) vascular dea:hr ;.~ung the first 5 weeks among palienl~ 
allocated aspinn compared .wilh 3MO6 ( I  I  .S%J among those allocated placebo 
tablets. Among those dncbarged abve. remfarctionr in huspital were 7 versus 
IO  and strokes were I  wnus 2 IMI  = myocardlal mfarilionl. 
Antiplatelet therapy. The present trial indicates that I 
month of low dose aspirin, started immediately in 1,000 
patients with suspected acute myocardial infarction, would 
typically avoid about 25 deaths and !O-I5 nonfatal reinfarc- 
tions or strokes. and that much of this benefit persists well 
beyond this short treaiment period. Coni nuation of anti- 
platelet therapy for 2-3 years in 1,000 postilfarction patients 
would, moreover, typically prevent about a)itrrher 20 deaths 
and afirrrhcr 30 nonfatal events (3). 
The optimal dose, and frequency of dosing, of aspirin 
remains uncertain. The definite reductions in vascular events 
observed with I60 mglday in ISIS-2 resemble those observed 
with hiat er doses (300-1.500 mg/day) in the long-term trials 
(T&e 3;. ::ighii dOSiS O f  ZSpiik ZZ ~~<iXi! tiiej more 
gastro:oxic (8) than lower doses, but do not appear to be any 
more effective (3). At present, therefore, when iong-term 
antiplatelet herapy is IO be used after myocardial infarction, 
unstable angina, transient cerebral &hernia or stroke, a 
dose of about I60 mg/day may be preferred. 
The combination of streptokinase and aspirin. This com- 
bination appears to have serious side effects that are no more 
frequent than those of streptokinase alone. Yet, the combi- 
nation reduces the risk of disabling or fatal stroke and of 
reinfarction, as well as reducing mortality much more sub- 
stantially than either agent does alone. For patients in ISIS-2 
admitted early after the onset of pain, the combination 
appeared to reduce 5 week mortality by about one-half, and 
even when used after a delay of several hours, it appeared ICI 
reduce mortality by about one-third. For example, among 
those entered 13-24 h after the onset of pain the mortality 
reduction was 38% + IS (45/608 versus 71/614), with appar- 
ently equal contributions from aspirin and from streptoki- 
nase (Fig. 3). Overall, therefore, among patients treated up 
to 24 h after pain onset, the combination of streptokinase and 
aspirin reduced the odds of vascular death by 43% + 5, with 
a lower confidence limit of 34%. The npparent effect of 
streptokinase is a little better in ISIS-2 than in some other 
trials (Fig. 5). but still the combination of streptokinase and 
aspirin is likely to reduce 5 week mortality by more than 
one-third for a wide range of patients, avoiding about 50 
deaths (or more, if antiplatelet therapy is continued for a 
longer period) among every 1,000 patients treated. 
In ISIS-2, the increase in reinfarction-and, hence. pre- 
sumably in reocclusion-produced by streptokinase alone 
was avoided if streptokinase was given in combination with 
aspirin. If fibrinolytic and antiplatelet therapies are com- 
bined, then it is not clear whether additional interventions to 
avoid reocclusion (for example, anticoagulants or angio- 
plasty) will confer additional benefit. But, it is clear, how- 
ever, that streptokinase and aspidn w;ll reduce both rein 
farction and death. even if other interventions a:c not used. 
This finding substantially simplifies the routins: use of fibri- 
nolytic therapy. 
Clinical implications. The initial diagnosis of myocardial 
infarction, and decisions about acute treatment, depend 
largely on the physician’s judgment of the clinical history 
and of the admission ECG. Such decisions cannot, of 
course, take into account information available only later 
from cardiac enzyme estimation or coronary angiography. 
ISIS-2 is dtrectly relevant to acute treatment, for the princi- 
pal en:ry criterion was that the responsible physician sus- 
pected acute myocardial infarction on the basis of the 
clinical presentation alone (although in practice 98% of 
patients had some ECG abnormality). The absolute mortal- 
ily reductions appear to be greatrbi fui P&enis ai gicatcst 
risk of death (for example, women, older patients, hypoten- 
sive patients, patients with a previous myocardial infarction 
or with an anterior infarction; see Lancet report [I]). But, 
even though the absolute benefits produced by streptokinass 
and by aspirin may be largest among high-risk pa:ients, the f 
may still also be worthwhile in many categories of patients at 
below-average risk of cardiac death. Furthermore, the ben- 
efits of stnptokinase may also outweigh the risks even 
among many patients who have some relative contraindica- 
tion (for example, recent use of streptokinase or an old 
history of stroke or of gastrointestinal hemorrhage or ulcer). 
For streptokinase, ISIS-2 does not support the suggestion 
(1 I) that the benefit among those treated within the first hour 
is much greater than among those treated slightly later (Fig. 
3); but, a small decrease in the median time of treatment (for 
example, from 5 h IO 4 h 1141) does produce a small 
improvement in the mortality reduction (for example, from 
20% LO 23%; Fig. 5). Worthwhile improvements might, 
therefore, be achieved by simple measures, such as encour- 
agement of prompt hospital admission and starting treatment 
in the emergency room before transfer to a coronary care 
I3A 
unit. It might, however, be best to delay fibrinolytlc treat- 
ment until hospital admission unless the patient’\ condmon 
can be monitored during and after infusion, for streptokma\e 
produces some side effects (for example, sudden profound 
hvpotension) that, although generally easy to manage m 
hospital. do require prompt medical attention. 
Aspirin does not require particularly careful momtonng. 
and it might well be appropriate to start it a5 yoon as pos5lblc 
(in the home, ambulance, or  emergency room) provided 
there are -to clear contraindications. Short-term antlplatelet 
therapy is likely to be applicable to almost all patient\ with 
suspected myocardial infarction. since the side effects of low 
dose aspirin seem negligible and the drug cost3 are small. 
Aspirin could be used widely not only in developed countrle\ 
but also in countries with limited medical resources. If I 
month of low dose aspirin were to be given to just I million 
new patients a year-which is only a fraction of the world- 
wide total with suspected acute myocardial infarction-then 
a few tens of thousands of deaths, reinfarctions. and strokes 
could be avoided or  substantially delayed (and these benefits 
could be doubled if low dose aspirin were continued for 2t 
least a few more years [3]). 
Although further research may eventually identify some 
fibrinolytic or  antithrombotic regimens more effective than 
those tested in ISIS-2, streptokinase and aspirin are practi- 
cable and are of demonstrated value and safety. If both are 
used widely. they shou!d avoid several tens of thousands of 
deaths each year. 
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